secwatch.observer — SEC 8-K summary
======================================

Issuer:     Barinthus Biotherapeutics plc. (BRNS)
CIK:        0001828185
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0001828185-25-000036
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Barinthus Bio Q1 loss widens to $19.6M; CFO Brown out, CEO Enright takes PFO; presents Phase 2 HBV data
--------------------------------------------------------------------------------

- Net loss $19.6M ($0.49/share) vs $15.5M ($0.40) in Q1 2024; R&D spending down to $8.3M from $11.1M.
- Cash $100.6M as of Mar 31, down from $112.4M; company expects runway into 2027.
- CFO Gemma Brown terminated Apr 30 in restructuring; CEO William Enright named principal financial officer, Brown stays as principal accounting officer until successor.
- HBV003 trial: 33% (15/45) of low baseline HBsAg participants achieved ≥1 log decline; 71% met NUC discontinuation criteria; no SAEs.
- IM-PROVE II: 25% (2/8) of participants with baseline HBsAg <1000 IU/mL reached functional cure; all seroconverted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828185/000182818525000036/0001828185-25-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828185/000182818525000036/brns-20250501.htm
  HTML page:      https://secwatch.observer/filing/0001828185-25-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer